Real-world comparison of erenumab and galcanezumab

Key messages

• In real-world clinical practice, patients who are switched from erenumab to galcanezumab report similar improvements in migraine symptoms.
• Both treatments were well-tolerated, with constipation being the most common side effect reported with erenumab and injection site reaction the most common with galcanezumab treatment.
• The majority of patients discontinued erenumab or galcanezumab treatment due lack of efficacy, but insurance issues and side effects are also contributory factors.